Ann: PYC Expands US Executive Leadership Team, page-14

I've watched the progress at PYC over the last few months and been pleasantly surprised. I think they're on the right track, they've chosen the right technology, and they've got into bed with the right people. I'm not sure about their latest hires, but time will tell.

I think science at Serepta isn't worth the time of day, and no-one should compare PYC to Serepta. Without the help of certain people at the FDA who were more concerned about the influence of patient advocacy groups than the standard of their science, Serepta would be just another struggling biotech, Fortunately, it seems that Biden is going to pass on Woodcock.